Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New artery-delivered combo shows promise against bone cancer

NCT ID NCT06562673

Disease control Sponsor: Shanghai 6th People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new approach for osteosarcoma (bone cancer) in 10 patients aged 12-40. The treatment combined standard chemotherapy with a targeted drug (Endostar) and cisplatin delivered directly into the artery supplying the tumor. The goal was to see if this method is safe and increases tumor cell death before surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

10 people

The number who actually took part.

Started

Dec 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of osteosarcoma patients aged 12-40 years old; 2. Accept to receive treatment with neoadjuvant chemotherapy regimen and completing the standard treatment course; Voluntary informed consent, joining the study with good compliance. 3. Have detailed medical data (such as medical history data, laboratory reports of blood routine and liver and kidney functions, pathology reports, etc.), and complete records of postoperative follow-up. Exclusion Criteria: 1. Combined history of acute injury, infection and surgery in the last 3 months; 2. Those with severe liver and kidney function abnormalities; 3. Those who are using anti-inflammatory drugs; 4. Pre-existing hematologic diseases before treatment; 5. Combined with other malignant tumors; 6. Diagnosed with autoimmune disease or using steroid drugs for more than 1 month before treatment; 7. Suffering from mental illness or cognitive dysfunction.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bone cancer osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone cancer Osteosarcoma

Contacts and locations

Locations

  • Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital,

    Shanghai, 200233, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.